CONMED : Investor Presentation

Investor Presentation

Q3 2022 Earnings

Curt R. Hartman

Chair of the Board, President, and Chief Executive Officer

Todd W. Garner

Executive Vice President and Chief Financial Officer

October 26, 2022

Forward-Looking Information

This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks

and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this presentation involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those

expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this presentation include, but are not limited to, the risks posed to the Company's business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability; any assumptions underlying any of the foregoing, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2021 and other risks and uncertainties which may be detailed from time to time in reports filed by CONMED with the SEC.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performancemeasures prepared in accordance with GAAP.

2

CONMED Vision

Empower healthcare providers worldwide to deliver

exceptional outcomes for patients.

Focus behind the Vision

People, Products, Profitability

3

Objectives for Our Shareholders

▪ Aggregate growthand profitability over the long term to significantly

increase the valuation of the company

▪ Increase our market sharein large and attractive markets

▪ Deliver above-marketrevenueand profitability growthover the long term

4

Orthopedics: Large, Attractive Markets
	Category	Description		Market Size and Competitors	Dollar Value of 1 Market Share Point
	Sports		$4.4 to $4.6 Billion
	Devices for repair of soft	▪	Arthrex	▪	Stryker	~$45M
	Medicine	tissue injuries in joints	▪	DePuy Mitek (J&J)
	▪	▪	Zimmer Biomet
				Smith & Nephew
	Allograft	Exclusive commercial	$375 to $425 Million
2022 Sept YTD	▪	Allosource			~$4M
rights to MTF allograft
Tissue	▪	LifeNet
	tissue	▪	RTI
		Surgical drills and saws	$1.4 to $1.6 Billion
	Powered	▪	DePuy Synthes (J&J)			~$15M
	with related single-use	▪
				Stryker
	Instruments	accessories	▪	Medtronic (Midas Rex / Xomed)
US			▪	Zimmer Biomet
36%		High-definition surgical	$1.8 to $2.0 Billion
	Surgical	▪	Stryker
International	visualization systems to	▪	Olympus	~$19M
Visualization	enable minimally invasive	▪	Arthrex	▪	Richard Wolf
64%	▪	Karl Storz	▪
		Smith & Nephew
		arthroscopic surgery
		Comprehensive portfolio	$4.4 to $4.6 Billion
		▪	Stryker
74%	Foot and	includes implants,	▪	DePuy Synthes			~45M
fracture systems,	▪	Paragon 28
		(J&J)
	Ankle			▪
Recurring, single-use revenue	biologics, and related	▪	Arthrex		Treace
	hardware
	Total						~$128M
	60% to 70% in Surgery Centers in the U.S.	~13% growth for total
	Orthopedics
							company
							5